The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts.
 
Kathleen N. Moore
Consulting or Advisory Role - Advaxis; AstraZeneca (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Immunogen (Inst); TESARO (Inst); VBL Therapeutics (Inst)
Travel, Accommodations, Expenses - Novocure; Takeda Milenium
 
Ursula A. Matulonis
Consulting or Advisory Role - AstraZeneca; Genentech; Immunogen; Merck KGaA; Tesaro
 
David M. O'Malley
Honoraria - Clovis Oncology
Consulting or Advisory Role - Amgen; AstraZeneca; Clovis Oncology; Eisai; Genentech/Roche; Janssen Oncology; Novocure; Tesaro
Research Funding - Ajinomoto (Inst); Amgen (Inst); Array BioPharma (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); EMD Serono (Inst); Ergomed (Inst); Genentech/Roche (Inst); Immunogen (Inst); Immunogen (Inst); Janssen Research & Development (Inst); PharmaMar (Inst); Regeneron (Inst); Stem CentRx (Inst); VentiRx (Inst)
 
Jason A. Konner
Consulting or Advisory Role - Clovis Oncology; Genentech/Roche
Research Funding - AstraZeneca/MedImmune; Genentech/Roche; TapImmune Inc.
 
Lainie P. Martin
Honoraria - ImmunoGen
 
Raymond P. Perez
Consulting or Advisory Role - Pharmaceutical Research Associates
Research Funding - Agensys (Inst); Altor BioScience (Inst); Bristol-Myers Squibb (Inst); Dompé Farmaceutici (Inst); Genentech/Roche (Inst); Immunogen (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); Millennium (Inst); Novartis (Inst); Onyx (Inst); Regeneron (Inst); TetraLogic Pharmaceuticals (Inst)
 
Todd Michael Bauer
Employment - Sarah Cannon Research Institute; Tennessee Oncology
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immunogen (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); MabVax (Inst); MedImmune (Inst); medpacto (Inst); Merck (Inst); Merrimack (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Principa Biopharma (Inst); Stemline Therapeutics (Inst)
 
Lucy Gilbert
No Relationships to Disclose
 
Shelly Marie Seward
Speakers' Bureau - AstraZeneca; Genentech
 
Amit M. Oza
Honoraria - WebRx
Consulting or Advisory Role - Amgen; Clovis Oncology; Immunovaccine; Verastem
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Merck (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Rodrigo Ruiz-Soto
Employment - ImmunoGen
 
Michael J. Birrer
Consulting or Advisory Role - Acceleron Pharma; Merrimack; Oxigene; Roche/Genentech; Sanofi; Threshold Pharmaceuticals